Thomas Jandl

Assistant Professor

Stony Brook University Hospital
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Thomas Jandl is an Assistant Professor at Stony Brook University Hospital in the United States. His research primarily focuses on the application of convalescent plasma for the treatment of severe COVID-19 infections, particularly in cancer patients. Dr. Jandl's work contributes to the understanding of innovative therapeutic strategies in critical care settings.

Articles (2)

The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse large B cell lymphoma (DLBCL) cohort is reported. Patients received intravenous odronextamab in 21-day cycles until progression or unacceptable toxicity, with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS) risk. The primary endpoint was objective response rate (ORR). Secondary endpoints included complete response (CR) rate, duration of response, progression-free survival (PFS) and overall survival. A total of 127 patients were enrolled. At the 29.9-month efficacy follow-up, the ORR was 52.0% and CR rate was 31.5%. Median durations of response and CR were 10.2 and 17.9 months, respectively. Undetectable minimal residual disease at cycle 4 day 15 was associated with PFS benefit. With a step-up of 0.7 to 4 to 20 mg ( n = 60), CRS was the most common treatment-emergent adverse event (53.3% (grade ≥3, 1.7%)). No immune effector cell-associated neurotoxicity syndrome was reported. Infections were reported in 82/127 (64.6%) patients (grade ≥3, 38.6%; coronavirus disease 2019, 18.1% (grade ≥3, 12.6%)). In conclusion, odronextamab showed encouraging efficacy in heavily pretreated R/R DLBCL and generally manageable safety with supportive care. Clinical trial registration: NCT03888105 .

Year:

2025

Year:

2020

Collaborators (4)

Tae Min Kim

Seoul National University Hospital

SOUTH KOREA
View details

Jan Walewski

Professor of Medicine, Consultant in Medical Oncology

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND
View details

JIN SEOK KIM

Associate Professor

Severance Hospital

SOUTH KOREA
View details

H. Miles Prince

Peter MacCallum Cancer Institute

AUSTRALIA
View details